Billie Heflin

Researcher

UAMS

Also affiliated: Arkansas Department of Agriculture (2026)

Faculty Researcher

4 h-index 21 pubs 74 cited

Research Areas

Biomedical Subjects

Links

ORCID

OverviewAI-generated summary

Billie Heflin's research focuses on investigating the pharmacological and molecular mechanisms underlying various cancers, with a particular emphasis on melanoma and glioblastoma. Heflin has explored the anti-cancer properties of natural compounds, such as those derived from Trametes versicolor mushrooms, and synthetic analogs. Recent work includes studying the anti-glioblastoma effects of monensin and its derivatives in organoid models and examining how resveratrol influences major histocompatibility complex class I antigen presentation in melanoma cells. Additionally, Heflin's research has investigated the role of specific proteins like S100b and EZH2 in cancer cell apoptosis and immune response, utilizing techniques such as CRISPR/dCas9-KRAB for gene suppression. Heflin collaborates with researchers at the University of Arkansas for Medical Sciences, including Megan R. Reed and Brian Koss, and has published 21 papers with a total of 70 citations, holding an h-index of 4.

Metrics

h-index: 4
Publications: 21
Citations: 74

Selected Publications

Abstract 6545: Characterizing ATF6 activation-driven mechanisms improving ICB efficacy (2026)

Cancer Research DOI OpenAlex
Abstract 5189: Generating EZH2-inhibitor resistant CAR-T cells to sustain function for combination therapy (2026)

Cancer Research DOI OpenAlex
685 EZH2 inhibition impairs CD8+ CAR-T cell persistence (2025)

Regular and Young Investigator Award Abstracts DOI OpenAlex
691 ATF6 activation promotes ICB response in melanoma (2025)

Regular and Young Investigator Award Abstracts DOI OpenAlex
Evaluation of the Activity of Monensin and Its Analogs for Modulation of Stem-like Cell Functionality in 2D and 3D Breast Cancer Models (2025)

ACS Pharmacology & Translational Science 1 citation DOI OpenAlex
Monensin and Its Analogs Exhibit Activity Against Breast Cancer Stem-Like Cells in an Organoid Model (2025)

bioRxiv (Cold Spring Harbor Laboratory) DOI OpenAlex
EZH2 loss during metabolic stress drives restoration of MHC class I machinery in melanoma (2025)

iScience 1 citation DOI OpenAlex
1132 Enhancing melanoma therapy efficacy by protecting EZH2 activity in T cells (2024)

Regular and Young Investigator Award Abstracts DOI OpenAlex
538 ATF6 activation in melanoma promotes anti-tumor immunity and improves ICB therapy response (2024)

Regular and Young Investigator Award Abstracts DOI OpenAlex
Abstract 584: Synergistic action of ATF6 and EZH2 in sensing metabolic stress to boost anti-tumor immunity (2024)

Cancer Research DOI OpenAlex
Synthesis and Anti‐Melanoma Activity of Acryloyl Pyridinone Analogues (2023)

Chemistry & Biodiversity 1 citation DOI OpenAlex
536 EZH2 senses metabolic stress to restore MHC-I antigen presentation and ICB response in metastatic melanoma (2023)

Regular and Young Investigator Award Abstracts DOI OpenAlex
Resveratrol induces major histocompatibility complex class I antigen presentation in a STING-dependent and independent manner in melanoma (2023)

Molecular Immunology 5 citations DOI OpenAlex
Abstract LB041: EZH2 and ATF6 sense metabolic stress to balance MHC class I antigen presentation in melanoma (2023)

Cancer Research DOI OpenAlex
CRISPR/dCas9-KRAB-Mediated Suppression of S100b Restores p53-Mediated Apoptosis in Melanoma Cells (2023)

Cells 9 citations DOI OpenAlex